Karyopharm Therapeutics Files 8-K
Ticker: KPTI · Form: 8-K · Filed: Dec 3, 2024 · CIK: 1503802
| Field | Detail |
|---|---|
| Company | Karyopharm Therapeutics Inc. (KPTI) |
| Form Type | 8-K |
| Filed Date | Dec 3, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, financial-statements
TL;DR
Karyopharm filed a routine 8-K, no major news.
AI Summary
Karyopharm Therapeutics Inc. filed an 8-K on December 3, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a routine disclosure for Karyopharm Therapeutics Inc., indicating the submission of required financial statements and exhibits to the SEC.
Risk Assessment
Risk Level: low — This filing is a standard 8-K for financial statements and exhibits, not indicating any new material events or risks.
Key Players & Entities
- Karyopharm Therapeutics Inc. (company) — Registrant
- December 3, 2024 (date) — Date of report
- 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Karyopharm Therapeutics Inc.?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as required by the SEC.
On what date was this 8-K report filed?
The report was filed on December 3, 2024.
What is the principal executive office address for Karyopharm Therapeutics Inc.?
The principal executive office address is 85 Wells Avenue, 2nd Floor, Newton, Massachusetts 02459.
What is the state of incorporation for Karyopharm Therapeutics Inc.?
Karyopharm Therapeutics Inc. is incorporated in Delaware.
Does this filing announce any new material events or financial results?
Based on the provided text, this filing is primarily for routine disclosures (Regulation FD, Financial Statements, Exhibits) and does not explicitly announce new material events or specific financial results.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2024-12-03 07:09:59
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value KPTI Nasdaq Global Select
Filing Documents
- d916753d8k.htm (8-K) — 25KB
- d916753dex991.htm (EX-99.1) — 30KB
- g916753g1203044035755.jpg (GRAPHIC) — 4KB
- 0001193125-24-269398.txt ( ) — 187KB
- kpti-20241203.xsd (EX-101.SCH) — 3KB
- kpti-20241203_lab.xml (EX-101.LAB) — 18KB
- kpti-20241203_pre.xml (EX-101.PRE) — 11KB
- d916753d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit 99.1 relating to Item 7.01 shall be deemed to be furnished, and not filed: 99.1 Press release issued by Karyopharm Therapeutics Inc. on December 3, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KARYOPHARM THERAPEUTICS INC. Date: December 3, 2024 By: /s/ Michael Mano Michael Mano Senior Vice President, General Counsel and Secretary